Phil_Hertits Posted - 10 hours ago

@occidental what about $TLTFF? They've gotten substantially good data so far.

PhantomZ Posted - 12 hours ago

$CGON CGON data: good but not quite long term data as $TLTFF so far IMHO 6 month DOR = 52 out of 97 patients = 54% 12 month DOR = 29 out of 83 patients= 34.9% 21 months DOR = 14 out of 69 patients = 20% Vs TLTFF ( only 2 treatments) 12 months 40% CR 15 months 38% CR Durable efficacy is key otherwise it shows that the minute you stop repetitive treatments, then CR rate goes down significantly and hence were they really CR or stable disease? IMHO. TLTFF 1 or 2 treatments and longerm longer durable CR seen. Do your DD

PhantomZ Posted - 14 hours ago

$CGON 79 out of 105 patients are CR at any time point. At 12 months 29 patients were still CR and 22 patents were pending data ( 22 out of 105 have not yet reached 12 months IMO). So 29 out of 83 are CR at 12 months , that’s 34.9% after 27 treatments? $TLTFF has Ruvidar at 40% CR at 12 months after only 2 treatments and CR is probably going higher going forward IMHO. TLTFF 30$ million MC soon BTD

GMcB Posted - 04/10/24

$TLTFF $CGON

GMcB Posted - 04/10/24

$TLTFF

Reconsider Posted - 04/09/24

$TLTFF https://stockhouse.com/news/newswire/2024/04/09/this-company-s-photo-dynamic-therapy-transforming-cancer-treatment

TheTinMan Posted - 04/09/24

$CGON If you want a better long term investment check out Theralase Technologies (TLTFF / $TLTFF ), Phase II trial for bladder cancer treatment with better results and only 1 or 2 treatments needed with zero adverse effects.

TheTinMan Posted - 04/09/24

@Chris_Trade @Runmaster83 @claudiaSoon @IBHappySoon If you want a better long term investment check out Theralase Technologies (TLTFF / $TLTFF ), Phase II trial for bladder cancer treatment with better results and only 1 or 2 treatments needed with zero adverse effects.

Sciencerules Posted - 02/09/24

$TLTFF Halted?

PhantomZ Posted - 02/08/24

$TLTFF $CGON $URGN $IBRX $MRK BCG UnResponsive NMIBC significantly undervalued, things should definitely heat up in the next few weeks/ months IMHO https://stockhouse.com/news/press-releases/2024/02/08/dr-michael-jewett-joins-theralase-r-to-help-complete-enrollment-in-the-phase-ii

Jd_Martin Posted - 02/06/24

$TLTFF Good action after management did another PP but this time pretty quick turnaround with a large insider buyer component. Market seems positive about the overall situation.

PhantomZ Posted - 01/15/24

$TLTFF $IBRX $MRK $PFE $URGN BCG Unresponsive NMiBC CIS Amazing results after 1-2 treatments single agent intravescicle Treatment. Going forward they have optimized procedure to giveup to 3 treatments IMHO https://www.urologytimes.com/view/photodynamic-therapy-tld-1433-shows-initial-promise-in-nmibc

SabaiSabai Posted - 01/15/24

$TLTFF market continues to snub this one despite 360 and 450 day CR data improving with almost every update. Is this only about the cash situation or does the market just not believe this outlier protocol is going to be successful even if it gets commercialized? I have begun to think only CR data head and shoulders above the commercially available competing protocols will lead to some success. The FDA and community at large have their favored protocols and Theralase is trying to be taken seriously at the big boy table with a community enamored by immunotherapy protocols and the potential for endless instillations. Meanwhile the chairman of the board now sends out promotional email blasts to investors. So yeah…credibility issues abound with this one

STCKPRO Posted - 01/15/24

$TLTFF NEW ARTICLE : Theralase provides encouraging interim results for Phase II study on bladder cancer treatment https://www.stck.pro/news/TLTFF/72761949/

STCKPRO Posted - 01/15/24

$TLTFF NEW ARTICLE : Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study https://www.stck.pro/news/TLTFF/72753808/

RenDragon Posted - 12/30/23

$LODE is my only non-pharma stock and definitely the weirdest. Artificial Intelligence, Mining, Bio-Fuels, Battery Recycling..no wait, Solar Panel Recycling. Property, strategic investments…. basically it’s all over the place. It’s only connection to my Pharma shares is that it also doesn’t make any money. The people involved in this company are either some of the most brilliant intellectuals…. or best bullshitters and delusional nutters in the USA. And finally my unloved $TLTFF. The numbers in its phase 2 for bladder cancer are very good but its share price has slowly sunk. The company talks about transferring the technology for use with breast cancer and Glioma, but that’s a rather different method of delivery than filling the bladder with light activated Photo Dynamic Compounds and then sticking a torch up ya peehole. Regardless, it seems a better treatment than what’s available and who wants to lose their bladder!

RenDragon Posted - 12/30/23

$CAPR $CAPR $NGENF $ATBPF $LODE $TLTFF Happy NY from NZ everyone. Plenty of frustrations in 2023 but things have been moving in the right direction if slowly. 2024 is truly going to be pivotal for most of my stocks. Of course, we were also told that in 2023, 2022, 2021 etc by the CEO’s of several of these companies but there is definitely a convergence in my shares for the next 12 months. My No.1 $CAPR is looking good for an accelerated approval along with sales networks in the USA and Japan already in place thanks to NS Pharma. The first cohort in the phase 3 Duchenne muscular dystrophy trial will read-out in late 2024 as well. If successful we should ultimately see CAP-1002 diversify in to all sorts of heart and muscle indications. We should also hear more about the mystery exosome partner and indication. CAPR’s exosome delivery systems could be transformational.

STCKPRO Posted - 12/15/23

$TLTFF NEW ARTICLE : Theralase Technologies CEO Roger DuMoulin-White talks Phase II clinical bladder cancer trial, progress with FDA https://www.stck.pro/news/TLTFF/70384799/

PhantomZ Posted - 12/13/23

$TLTFF numbers keep improving! https://theralase.com/wp-content/uploads/2023/12/Theralase-Corporate-Presentation-12-08-2023.pdf

PhantomZ Posted - 11/30/23

$TLTFF $IBRX $MRK $JNJ when will the market wake up? NMIBC At 450 days 36% CR vs 19% for Keytruda and 23.5% for Adstiladrin . 90% more effective than Keytruda, 50% more effective than Adstiladrin and numbers getting better and better each 90 days forward. One single treatment and single agent ( plus one maintenance at day 180). IR patients may be reclassified as CR if CIS confirmed in Upper tract. All IMHO

Stock_Titan Posted - 11/29/23

$TLTFF Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement Article Available on StockTitan Website.

Stock_Titan Posted - 11/17/23

$TLTFF Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing Article Available on StockTitan Website.

SabaiSabai Posted - 11/10/23

$TLTFF does anyone find it concerning that the CR results are so good and yet this company has so much difficulty raising money? We know the science is credible so this appears to be a investor distrust and lack of management credibility.

SabaiSabai Posted - 10/30/23

$TLTFF is anyone here participating in the current offering?

Stock_Titan Posted - 10/23/23

$TLTFF Theralase(R) Announces Brokered LIFE Financing https://www.stocktitan.net/news/TLTFF/theralase-r-announces-brokered-life-6rkmw9rcqwz9.html

STCKPRO Posted - 10/23/23

$TLTFF NEW ARTICLE : Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study https://www.stck.pro/news/TLTFF/65478285/

Stock_Titan Posted - 10/23/23

$TLTFF Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study https://www.stocktitan.net/news/TLTFF/theralase-r-optimizes-phase-ii-bladder-cancer-clinical-e6965r3rfhap.html

SabaiSabai Posted - 10/16/23

$TLTFF 180 and 270 day optimized CR data looking very strong.

Stock_Titan Posted - 10/05/23

$TLTFF Theralase(R) Files US Patent for Enhanced Immunotherapy https://www.stocktitan.net/news/TLTFF/theralase-r-files-us-patent-for-enhanced-3dyu7rbi8ibt.html #patent

OldValueInvestor Posted - 09/30/23

$TLTFF folks think this will bounce back to the 10/20 SMA next week or another flush?